137 related articles for article (PubMed ID: 35297649)
21. Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab.
Liu R; Zhao X; Guo W; Huang M; Qiu L; Zhang W; Zhang Z; Li W; Zhu X; Chen Z
Clin Transl Oncol; 2020 Jun; 22(6):928-934. PubMed ID: 31571151
[TBL] [Abstract][Full Text] [Related]
22. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
Ito T; Takashima A; Yamazaki K; Yukami H; Uetake H; Tsuda M; Suto T; Moriwaki T; Sugimoto N; Ojima H; Takii Y; Yasui H; Esaki T; Tsuji A; Goto M; Saruta M; Otsu S; Shinozaki K; Fujiwara T; Tamura T; Baba E; Shiozawa M; Denda T; Ueno H; Nagashima K; Shimada Y
Int J Clin Oncol; 2022 Sep; 27(9):1450-1458. PubMed ID: 35861943
[TBL] [Abstract][Full Text] [Related]
23. HER2 targeted therapy in colorectal cancer: New horizons.
Suwaidan AA; Lau DK; Chau I
Cancer Treat Rev; 2022 Apr; 105():102363. PubMed ID: 35228040
[TBL] [Abstract][Full Text] [Related]
24. HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study.
Chen PC; Yeh YM; Chu CT; Su PF; Chiu PH; Lin BW; Chen SH; Lin PC; Lee CT; Chen HHW; Chen CC
Eur J Cancer; 2023 Mar; 181():62-69. PubMed ID: 36640475
[TBL] [Abstract][Full Text] [Related]
25. Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data.
Fernandes LE; Epstein CG; Bobe AM; Bell JSK; Stumpe MC; Salazar ME; Salahudeen AA; Pe Benito RA; McCarter C; Leibowitz BD; Kase M; Igartua C; Huether R; Hafez A; Beaubier N; Axelson MD; Pegram MD; Sammons SL; O'Shaughnessy JA; Palmer GA
Clin Breast Cancer; 2021 Aug; 21(4):e340-e361. PubMed ID: 33446413
[TBL] [Abstract][Full Text] [Related]
26. Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
Liede A; Sebby W; Miriyala AKR; Potluri R; Mazumder D; Ghosh A; Papademetriou E; Kilpatrick R; Tyczynski JE
BMC Cancer; 2023 Jan; 23(1):78. PubMed ID: 36690978
[TBL] [Abstract][Full Text] [Related]
27. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
Wang JX; Wu HL; Zhu M; Zhou R
Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
[TBL] [Abstract][Full Text] [Related]
28. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.
Martin V; Landi L; Molinari F; Fountzilas G; Geva R; Riva A; Saletti P; De Dosso S; Spitale A; Tejpar S; Kalogeras KT; Mazzucchelli L; Frattini M; Cappuzzo F
Br J Cancer; 2013 Feb; 108(3):668-75. PubMed ID: 23348520
[TBL] [Abstract][Full Text] [Related]
29. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer.
Wang G; He Y; Sun Y; Wang W; Qian X; Yu X; Pan Y
Clin Transl Oncol; 2020 Jun; 22(6):813-822. PubMed ID: 31587152
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.
Nakamura Y; Okamoto W; Kato T; Esaki T; Kato K; Komatsu Y; Yuki S; Masuishi T; Nishina T; Ebi H; Sawada K; Taniguchi H; Fuse N; Nomura S; Fukui M; Matsuda S; Sakamoto Y; Uchigata H; Kitajima K; Kuramoto N; Asakawa T; Olsen S; Odegaard JI; Sato A; Fujii S; Ohtsu A; Yoshino T
Nat Med; 2021 Nov; 27(11):1899-1903. PubMed ID: 34764486
[TBL] [Abstract][Full Text] [Related]
31. EGFR Amplification in Metastatic Colorectal Cancer.
Randon G; Yaeger R; Hechtman JF; Manca P; Fucà G; Walch H; Lee J; Élez E; Seligmann J; Mussolin B; Pagani F; Germani MM; Ambrosini M; Rossini D; Ratti M; Salvà F; Richman SD; Wood H; Nanjangud G; Gloghini A; Milione M; Bardelli A; de Braud F; Morano F; Cremolini C; Pietrantonio F
J Natl Cancer Inst; 2021 Nov; 113(11):1561-1569. PubMed ID: 33825902
[TBL] [Abstract][Full Text] [Related]
32. Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.
Miller RS; Mokiou S; Taylor A; Sun P; Baria K
Breast Cancer Res Treat; 2022 May; 193(1):83-94. PubMed ID: 35194731
[TBL] [Abstract][Full Text] [Related]
33. Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.
Sartore-Bianchi A; Amatu A; Bonazzina E; Stabile S; Giannetta L; Cerea G; Schiavetto I; Bencardino K; Funaioli C; Ricotta R; Cipani T; Schirru M; Gambi V; Palmeri L; Carlo-Stella G; Rusconi F; Di Bella S; Burrafato G; Cassingena A; Valtorta E; Lauricella C; Pazzi F; Gambaro A; Ghezzi S; Marrapese G; Tarenzi E; Veronese S; Truini M; Vanzulli A; Siena S
Target Oncol; 2017 Aug; 12(4):525-533. PubMed ID: 28669023
[TBL] [Abstract][Full Text] [Related]
34. Impact of Metastasectomy in the Multimodality Approach for
Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
[TBL] [Abstract][Full Text] [Related]
35. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
[TBL] [Abstract][Full Text] [Related]
36. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
37. The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.
Hammerman A; Greenberg-Dotan S; Battat E; Feldhamer I; Bitterman H; Brenner B
Acta Oncol; 2015 Feb; 54(2):164-70. PubMed ID: 25350524
[TBL] [Abstract][Full Text] [Related]
38. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
40. RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine.
Valentini AM; Cavalcanti E; Di Maggio M; Caruso ML
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):539-544. PubMed ID: 30199395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
